Stewart Appelrouth Net Worth

The estimated Net Worth of Stewart Appelrouth is at least $74.3 Tisíc dollars as of 15 March 2024. Mr. Appelrouth owns over 90,910 units of AIM ImmunoTech Inc stock worth over $74,303 and over the last 8 years he sold AIM stock worth over $0. In addition, he makes $0 as Director at AIM ImmunoTech Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Appelrouth AIM stock SEC Form 4 insiders trading

Stewart has made over 8 trades of the AIM ImmunoTech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 90,910 units of AIM stock worth $30,000 on 15 March 2024.

The largest trade he's ever made was buying 126,000 units of AIM ImmunoTech Inc stock on 24 July 2018 worth over $39,060. On average, Stewart trades about 10,429 units every 63 days since 2016. As of 15 March 2024 he still owns at least 239,765 units of AIM ImmunoTech Inc stock.

You can see the complete history of Mr. Appelrouth stock trades at the bottom of the page.

Stewart Appelrouth biography

Stewart L. Appelrouth is Director of the company. He has served as a member of the Board of Directors since August 2016. Mr. Appelrouth is a certified public accountant and partner at Appelrouth Farah & Co., P.A., Certified Public Accountants and Advisors. Mr. Appelrouth is also a certified forensic accountant and possesses 40 years of experience in Accounting and Consulting. He is a member of or has affiliations with the AICPA, American College of Forensic Examiners, Association of Certified Fraud Examiners, Florida Bar Grievance Committee, Florida Institute of Certified Public Accountants and InfraGard Member, a national information sharing program between the Federal Bureau of Investigation and the private sector. Mr. Appelrouth graduated from Florida State University in 1975 and his Master’s Degree in Finance from Florida International University in 1980.

What's Stewart Appelrouth's mailing address?

Stewart's mailing address filed with the SEC is 2117 SW HIGHWAY 484, , OCALA,, FL, 34473.

Insiders trading at AIM ImmunoTech Inc

Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors a Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.

What does AIM ImmunoTech Inc do?

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

Complete history of Mr. Appelrouth stock trades at AIM ImmunoTech Inc

AIM ImmunoTech Inc executives and stock owners

AIM ImmunoTech Inc executives and other stock owners filed with the SEC include:

• William Mitchell,
  Chairman of the Board
• Thomas K. Equels Esq., J.D., M.S.,
  Exec. Vice Chairman, CEO & Pres
• Thomas Equels,
  Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
• Thomas K. Equels,
  Exec. Vice Chairman, CEO & Pres
• Peter W. Rodino III, Esq., J.D.,
  COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.
• Wayne Springate,
  Senior Vice President - Operations
• David Strayer,
  Chief Scientific & Medical Officer
• Ellen M. Lintal,
  CFO & Chief Accounting Officer
• Charles Jones,
  Investor Relations
• Stewart Appelrouth,
  Director
• Peter Rodino,
  Chief Operating Officer, General Counsel, Secretary
• Ellen Lintal,
  Chief Financial Officer
• Jodie Pelz,
  Controller
• Dr. David R. Strayer M.D.,
  Chief Scientific Officer & Medical Director
• Robert Dickey IV, M.B.A.,
  Chief Financial Officer
• Dr. Ralph Christopher Cavalli Ph.D.,
  VP of QC & Manufacturing
• Dr. Ralph Christopher Cavalli,
  VP of QC & Manufacturing
• Julie Mierau,
  Controller
• Dr. Carol A. Smith,
  Chief Manufacturing Officer & Deputy Chief Scientific Officer
• Ann Marie E. Coverly,
  Director of Admin. & HR and Deputy Investor Relations Coordinator
• Dr. David R. Strayer,
  Chief Scientific Officer & Medical Director
• Roy Robinson,
  Director
• Douglas Hillman,
  President, CEO and Director
• Donald Russell,
  Director
• Thomas E Whytas,
  Director
• David M Vosen,
  Director
• Technik Industries, Inc. El...,
  10% owner
• Kevin J Purcell,
  EVP and Chief Financial Office
• Robert J Mcgill,
  Director
• Mark Perkins,
  Executive V.P.
• Thomas Wright Cason,
  Executive Vice President, COO
• Commercial Bank First,
  10% owner
• Carmelo Russo,
  Executive V.P.
• David A Baldini,
  President and CEO
• Gary E Colbert,
  Executive VP and CFO
• J Mervyn Nabors,
  10% owner
• Nancy Bryan,
  Director